Asset Details
Do you wish to reserve the book?
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Do you wish to request the book?
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014
Overview
In patients with glioblastoma, the addition of bevacizumab to radiotherapy and temozolomide induction therapy and the use of bevacizumab maintenance therapy did not influence overall survival. Freedom from progression was slightly increased but at the cost of increased toxic effects.
Tumor progression in glioblastoma, the most common primary brain cancer,
1
,
2
is associated with deterioration in neurocognitive function,
3
,
4
decreased functional independence,
5
and a progressive decrease in health-related quality of life.
6
,
7
After surgical resection, the standard of care for patients with newly diagnosed glioblastoma and a good Karnofsky performance score (≥70, on a scale of 0 to 100, with higher numbers indicating better functioning) is concurrent radiotherapy and temozolomide, followed by adjuvant temozolomide.
8
–
11
The prognosis remains poor; no further improvements in outcomes have been documented since the introduction of radiotherapy–temozolomide therapy in 2005.
Glioblastomas are characterized by overexpression . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Biological and medical sciences
/ Brain Neoplasms - drug therapy
/ Brain Neoplasms - radiotherapy
/ Dacarbazine - adverse effects
/ Dacarbazine - analogs & derivatives
/ Dacarbazine - therapeutic use
/ Female
/ Humans
/ Male
/ NMR
/ Patients
/ Pharmacology. Drug treatments
/ Survival
/ Tumors of the nervous system. Phacomatoses
